Pericarditis
Photo credits: pixabay.com
Commented by Nico Popp on November 9th, 2026 | 23:05 CET
Billion-dollar opportunity in cardiac therapy: Cardiol Therapeutics, Kiniksa and Novo Nordisk
Created and Published on Behalf of Cardiol Therapeutics
The treatment of inflammatory heart diseases is becoming one of the most lucrative segments of the pharmaceutical industry. The only drug approved to date for recurrent pericarditis is expected to exceed USD 1 billion in revenue this year. While established industry heavyweights generate enormous revenues from injectable biologics, emerging biotechnology companies are preparing the next stage of development. The focus is on the search for oral therapies intended to open up access to treatment for a much broader patient population.
Read